- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06526195
Forsøg for at evaluere sikkerheden og effektiviteten af mekanisk kredsløbsstøtte hos patienter med fremskreden hjertesvigt (TEAM-HF)
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
Studieoversigt
Status
Detaljeret beskrivelse
Patients with heart failure (HF) suffer from a high degree of morbidity and mortality. Left ventricular assist device (LVAD) therapy has become the standard of care for the treatment of advanced HF patients who are deemed to be dependent on continuous intravenous inotropes, extending life expectancy, enhancing overall quality of life, and improving functional capacity. However, use of LVADs in ambulatory, non-inotrope dependent advanced HF population is limited. Elevated mean pulmonary artery pressure (PAP) secondary to left ventricular failure has emerged as a potential predictor of increased mortality risk for patients refractory to maximally tolerated guideline directed medical therapy (GDMT). In these patients, left ventricular failure with elevated mean PAP may represent objective criteria to identify advanced HF patients requiring heart replacement therapies such as LVAD.
The TEAM-HF IDE trial will enroll approximately 850 subjects with New York Heart Association (NYHA) Class IIIB/IV HF who had a prior heart failure hospitalization and an elevated mean PAP secondary to left ventricular failure. Elevated mean PAP will be identified using an implanted PAP monitoring sensor, the CardioMEMS PA Sensor. All subjects enrolled can have a previously implanted CardioMEMS PA Sensor or, if not, will be implanted with the CardioMEMS PA Sensor after enrollment. The overall objectives of TEAM-HF trial are two-fold: 1) To determine whether PAP can objectively identify patients most at risk for worsening HF and therefore most likely to benefit from earlier intervention with LVAD therapy and 2) To determine the benefit of LVAD therapy in non-inotrope advanced HF patients with elevated mean PAP refractory to GDMT.
The trial will include approximately 75 global sites and consists of a Randomized Arm and a Single Arm Registry.
The TEAM-HF Randomized Arm is a prospective, randomized, open-label study of the HeartMate 3 (HM3) left ventricular assist system (LVAS) versus continued GDMT in non-inotrope dependent HF patients. The objectives of the Randomized Arm are 1) To establish an objective disease-state criteria to trigger referral for a HM3 LVAS and 2) Demonstrate improvement in survival when non-inotrope dependent advanced HF patients are treated with the HM3 LVAS compared to being managed on medical therapy alone.
The TEAM-HF Single Arm Registry is a prospective, single-arm, open-label study of non-inotrope dependent HF patients who do not meet a mean PAP threshold after GDMT optimization. The objective of the Single Arm Registry is to characterize the progression of patients with non-inotrope dependent HF without elevated PAP.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Nourdine Chakouri, PhD
- Telefonnummer: 925-989-5982
- E-mail: nourdine.chakouri@abbott.com
Studiesteder
-
-
Copenhagen
-
Copenhagen, Copenhagen, Danmark, 2100
- Rekruttering
- Rigshospitalet
-
Kontakt:
- Christina Moeller
- Telefonnummer: +00 453 545 6757
- E-mail: Christina.Moeller@regionh.dk
-
Ledende efterforsker:
- Kasper Rossing, MD
-
-
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85006
- Trukket tilbage
- Banner-University Medical Center Phoenix
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72205
- Rekruttering
- Baptist Health Medical Center
-
Ledende efterforsker:
- Patrick Campbell, MD
-
Kontakt:
- Victoria Marren
- Telefonnummer: 678-654-0327
- E-mail: victoria.marren@baptist-health.org
-
-
California
-
Sacramento, California, Forenede Stater, 95816
- Rekruttering
- Sutter Medical Center
-
Kontakt:
- Jessica Mccall
- Telefonnummer: 916-887-4654
- E-mail: jessica.mccall@sutterhealth.org
-
Ledende efterforsker:
- Michael Gibson, MD
-
San Francisco, California, Forenede Stater, 94143
- Rekruttering
- University of California at San Francisco
-
Kontakt:
- Tyre Richardson
- Telefonnummer: (209) 650-5302
- E-mail: tyre.richardson@ucsf.edu
-
Ledende efterforsker:
- Shweta Motiwala, MD
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- Rekruttering
- Washington Hospital Center
-
Ledende efterforsker:
- Sheikh Farooq, MD
-
Kontakt:
- Hellina Birru
- Telefonnummer: 202-877-6334
- E-mail: hellina.t.birru@medstar.net
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32610
- Rekruttering
- Shands at the University of Florida
-
Ledende efterforsker:
- Mustafa Ahmed, MD
-
Kontakt:
- Erikson Walter
- Telefonnummer: 269-331-9581
- E-mail: erikson.walter@ufl.edu
-
Weston, Florida, Forenede Stater, 33331
- Rekruttering
- Cleveland Clinic Florida
-
Kontakt:
- Maria Mejia-Gomez
- Telefonnummer: 954-659-5888
- E-mail: mejiagm@ccf.org
-
Ledende efterforsker:
- Mauricio Velez, MD
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30309
- Rekruttering
- Piedmont Heart Institute
-
Ledende efterforsker:
- Catherine Marti, MD
-
Kontakt:
- Andrew Bailey
- Telefonnummer: 404-605-4098
- E-mail: Andrew.Bailey1@piedmont.org
-
Augusta, Georgia, Forenede Stater, 30901
- Rekruttering
- Piedmont Augusta Hospital
-
Ledende efterforsker:
- Darshak Karia, MD
-
Kontakt:
- Jennifer Hansen
- Telefonnummer: 706-724-2463
- E-mail: jennifer.hansen@piedmont.org
-
Marietta, Georgia, Forenede Stater, 30060
- Rekruttering
- WellStar Kennestone Hospital
-
Ledende efterforsker:
- Abdul Bikak, MD
-
Kontakt:
- Amuthanayaki Kanagaraj
- Telefonnummer: 470-793-7554
- E-mail: amuthanayaki.kanagaraj2@wellstar.org
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- University of Chicago
-
Kontakt:
- Kristen Hanauer
- Telefonnummer: 773-702-8716
- E-mail: kristen.hanauer@bsd.uchicago.edu
-
Ledende efterforsker:
- Nikhil Narang, MD
-
Oakbrook Terrace, Illinois, Forenede Stater, 60181
- Rekruttering
- Advocate Health & Hospitals Corporation
-
Kontakt:
- Mairead Delaney
- Telefonnummer: 708-684-4209
- E-mail: mairead.delaney@aah.org
-
Ledende efterforsker:
- Vinh Chau, MD
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46240
- Rekruttering
- St. Vincent Hospital
-
Ledende efterforsker:
- Ashwin Ravichandran, MD
-
Kontakt:
- Regina Margiotti
- Telefonnummer: 317-338-6151
- E-mail: Regina.Margiotti@ascension.org
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- Rekruttering
- University of Iowa Hospitals & Clinics
-
Kontakt:
- Page Scovel
- Telefonnummer: 319- 356-2585
- E-mail: Page-scovel@uiowa.edu
-
Ledende efterforsker:
- Anthony Panos, MD
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Rekruttering
- Kansas University Medical Center
-
Kontakt:
- Terry Christenson
- Telefonnummer: 515-210-2626
- E-mail: tchristenson3@kumc.edu
-
Ledende efterforsker:
- Zubair Shah, MD
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
- Afsluttet
- University of Kentucky
-
Louisville, Kentucky, Forenede Stater, 40202
- Rekruttering
- Norton Hospital
-
Kontakt:
- Laurie Michelle Jones
- Telefonnummer: 502-891-8699
- E-mail: laurie.jones@nortonhealthcare.org
-
Ledende efterforsker:
- Alkhalil Bassel, MD
-
-
Maine
-
Portland, Maine, Forenede Stater, 04102
- Rekruttering
- Maine Medical Center
-
Kontakt:
- Monica Palmeri
- Telefonnummer: 207-662-2090
- E-mail: monica.palmeri@mainehealth.org
-
Ledende efterforsker:
- Peter Kennel, MD
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
Kontakt:
- Bronwen Rees-Weidemann
- Telefonnummer: 617-726-5508
- E-mail: brees-wiedemann@mgh.harvard.edu
-
Ledende efterforsker:
- Erin Coglianese, MD
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48202
- Rekruttering
- Henry Ford Hospital
-
Kontakt:
- Zack Malouf
- Telefonnummer: 313-585-7068
- E-mail: zmalouf1@hfhs.org
-
Ledende efterforsker:
- Lindsey Aurora, MD
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Rekruttering
- Spectrum Health Butterworth Hospital
-
Kontakt:
- Stephanie Hanson
- Telefonnummer: 616-391-0284
- E-mail: stephanie.hanson@corewellhealth.org
-
Ledende efterforsker:
- Matthew Gonzalez, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55407
- Rekruttering
- Minneapolis Heart Institute
-
Ledende efterforsker:
- Mosi Bennett, MD
-
Kontakt:
- Kate Jappe
- Telefonnummer: 612-863-7347
- E-mail: Kate.Jappe@allina.com
-
Rochester, Minnesota, Forenede Stater, 55905
- Rekruttering
- Mayo Clinic
-
Kontakt:
- Colleen Irlbeck
- Telefonnummer: 507-266-6879
- E-mail: Irlbeck.Colleen@mayo.edu
-
Ledende efterforsker:
- Andrew Rosenbaum, MD
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64111
- Rekruttering
- St. Luke's Hospital
-
Ledende efterforsker:
- Timothy Fendler, MD
-
Kontakt:
- Amanda Huffman
- Telefonnummer: 816-932-0391
- E-mail: ahuffman@saint-lukes.org
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68198
- Rekruttering
- University of Nebraska Medical Center
-
Kontakt:
- Ryan Ruskamp
- Telefonnummer: 402-836-9779
- E-mail: ryan.ruskamp@unmc.edu
-
Ledende efterforsker:
- Adam Burdorf, DO
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- Rekruttering
- Hackensack University Medical Center
-
Ledende efterforsker:
- Kanika Mody, MD
-
Kontakt:
- Manuel Castillo
- Telefonnummer: 551-996-2136
- E-mail: Manuel.Castillo@hmhn.org
-
Newark, New Jersey, Forenede Stater, 07112
- Rekruttering
- Newark Beth Israel Medical Center
-
Ledende efterforsker:
- Igor Gosev, MD
-
Kontakt:
- Patel Bhargavi
- Telefonnummer: 516-600-1487
- E-mail: bhargavi.patel2@rwjbh.org
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87102
- Rekruttering
- New Mexico Heart Institute
-
Kontakt:
- Rebecca Jones
- Telefonnummer: 505-843-2827
- E-mail: Rebecca.Jones@lovelace.com
-
Ledende efterforsker:
- Dana Booth, MD
-
-
New York
-
Manhasset, New York, Forenede Stater, 11030
- Rekruttering
- North Shore University Hospital
-
Kontakt:
- Salome Reddy
- Telefonnummer: 516-600-1459
- E-mail: seliareddy@northwell.edu
-
Ledende efterforsker:
- Maria Avila, MD
-
New York, New York, Forenede Stater, 10032
- Rekruttering
- New York-Presbyterian/Columbia University Medical Center
-
Kontakt:
- Jessica Idumonyi
- Telefonnummer: 212-305-1368
- E-mail: joi2102@cumc.columbia.edu
-
Ledende efterforsker:
- Dor Lotan, MD
-
Rochester, New York, Forenede Stater, 14642
- Rekruttering
- University of Rochester Medical Center
-
Kontakt:
- Lori Caufield
- Telefonnummer: (585) 273-4956
- E-mail: lori_caufield@urmc.rochester.edu
-
Ledende efterforsker:
- Leway Chen, MD
-
The Bronx, New York, Forenede Stater, 10467
- Rekruttering
- Montefiore Medical Center - Moses Campus
-
Ledende efterforsker:
- Yogita Rochlani, MD
-
Kontakt:
- Sabrina Sicilia
- E-mail: ssicilia@montefiore.org
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27599
- Rekruttering
- University of North Carolina at Chapel Hill
-
Kontakt:
- Hanna Mixon
- Telefonnummer: (919) 962-4896
- E-mail: hanna_mixon@med.unc.edu
-
Ledende efterforsker:
- William Mostertz, MD
-
Charlotte, North Carolina, Forenede Stater, 28203
- Rekruttering
- Carolinas Medical Center
-
Kontakt:
- Dana Amaro
- Telefonnummer: 704-355-4794
- E-mail: dana.amaro@atriumhealth.org
-
Ledende efterforsker:
- Joseph Mishkin, MD
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45219
- Rekruttering
- Christ Hospital
-
Kontakt:
- Susanne Pasley
- Telefonnummer: 513-585-1777
- E-mail: susanne.pasley@thechristhospital.com
-
Ledende efterforsker:
- Emani Sitaramesh, MD
-
Cleveland, Ohio, Forenede Stater, 44195
- Rekruttering
- The Cleveland Clinic Foundation
-
Kontakt:
- Barbara Gus
- Telefonnummer: 216-445-6552
- E-mail: gusb@ccf.org
-
Ledende efterforsker:
- Michael Tong, MD
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73112
- Rekruttering
- Integris Baptist Medical Center
-
Kontakt:
- Jill Bethany Fife
- Telefonnummer: (405) 951-8607
- E-mail: bethany.fife@integrishealth.org
-
Ledende efterforsker:
- Luke Cunningham, MD
-
Tulsa, Oklahoma, Forenede Stater, 74104
- Rekruttering
- Oklahoma Heart Institute at Utica
-
Kontakt:
- Allyson O'Guin
- Telefonnummer: (918) 574-9253
- E-mail: allyson.oguin@hillcrest.com
-
Ledende efterforsker:
- Luis David Meggo Quiroz, MD
-
Tulsa, Oklahoma, Forenede Stater, 74136
- Rekruttering
- Saint Francis Hospital
-
Ledende efterforsker:
- Douglas Ensley, MD
-
Kontakt:
- Riley Pritzlaff
- Telefonnummer: 918-494-8500
- E-mail: rpritzlaff@saintfrancis.com
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Rekruttering
- Oregon Health & Science University
-
Ledende efterforsker:
- Johannes Steiner, MD
-
Kontakt:
- Ricardo Mendoza
- Telefonnummer: (503) 494-9511
- E-mail: Mendozri@ohsu.edu
-
-
Pennsylvania
-
Abington, Pennsylvania, Forenede Stater, 19001
- Rekruttering
- Abington Memorial Hospital
-
Kontakt:
- Colleen Marchand
- Telefonnummer: 215-481-4661
- E-mail: colleen.marchand@jefferson.edu
-
Ledende efterforsker:
- Alexander Shpilman, MD
-
Hershey, Pennsylvania, Forenede Stater, 17033
- Rekruttering
- Penn State Milton S. Hershey Medical Center
-
Ledende efterforsker:
- John Boehmer, MD
-
Kontakt:
- Amanda Donnangelo
- Telefonnummer: 717-531-0850
- E-mail: adonnangelo@pennstatehealth.psu.edu
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- University of Pennsylvania
-
Kontakt:
- Emma Markley
- Telefonnummer: 585-273-3760
- E-mail: Emma.markley@pennmedicine.upenn.edu
-
Ledende efterforsker:
- Himabindu Vidula, MD
-
Philadelphia, Pennsylvania, Forenede Stater, 15213
- Rekruttering
- University of Pittsburgh Medical Center (UPMC)
-
Ledende efterforsker:
- Gavin Hickey, MD
-
Kontakt:
- Abbey Sung
- Telefonnummer: 412-648-6024
- E-mail: sunga3@upmc.edu
-
Pittsburgh, Pennsylvania, Forenede Stater, 15212
- Rekruttering
- Allegheny General Hospital
-
Ledende efterforsker:
- Matthew Lander, MD
-
Kontakt:
- Laurie Machen
- Telefonnummer: 412-359-6181
- E-mail: Laurie.MACHEN@ahn.org
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Rekruttering
- Medical University of South Carolina
-
Ledende efterforsker:
- Arman Kilic, MD
-
Kontakt:
- Melissa Lamicq
- Telefonnummer: 954-683-4648
- E-mail: Lamicq@musc.edu
-
Columbia, South Carolina, Forenede Stater, 29203
- Rekruttering
- Prisma Health Midlands
-
Kontakt:
- Brooks Ferguson
- Telefonnummer: 843-442-0994
- E-mail: Brooks.Ferguson@prismahealth.org
-
Ledende efterforsker:
- James Ampadu, MD
-
Kontakt:
- Abigail Anderson
- Telefonnummer: 864-455-7629
- E-mail: Abigail.Anderson@prismahealth.org
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38120
- Rekruttering
- The Stern Cardiovascular Foundation
-
Kontakt:
- Rishi Bhula
- Telefonnummer: 901-271-2220
- E-mail: rishi.bhula@sterncardio.com
-
Ledende efterforsker:
- Todd Edwards, MD
-
-
Texas
-
Austin, Texas, Forenede Stater, 78705
- Rekruttering
- Ascension Texas Cardiovascular
-
Kontakt:
- Jennifer Mcsorley
- Telefonnummer: 702-427-2014
- E-mail: jennifer.mcsorley@ascension.org
-
Ledende efterforsker:
- Raymond Bietry, MD
-
Dallas, Texas, Forenede Stater, 75246
- Rekruttering
- Baylor University Hospital
-
Kontakt:
- Shelby Shull
- Telefonnummer: 214-818-2587
- E-mail: Shelby.Shull@BSWHealth.org
-
Ledende efterforsker:
- Cesar Guerrero-Miranda, MD
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Houston Methodist
-
Kontakt:
- Mary Kelly
- Telefonnummer: (346) 238-8240
- E-mail: makelly@houstonmethodist.org
-
Ledende efterforsker:
- Cindy Martin, MD
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- CHI St. Luke's Health Baylor College of Medicine Medical Center
-
Ledende efterforsker:
- Ajith Nair, MD
-
Kontakt:
- Wajeeha Abrar
- Telefonnummer: (713) 798-5404
- E-mail: Wajeeha.Abrar@bcm.edu
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- UTHealth Memorial Hermann
-
Kontakt:
- Lawana Self
- Telefonnummer: 713-486-6751
- E-mail: lawana.self@uth.tmc.edu
-
Ledende efterforsker:
- Nathan Sriram, MD
-
Plano, Texas, Forenede Stater, 75093
- Rekruttering
- The Heart Hospital Baylor Plano
-
Kontakt:
- Shelby McCoy
- Telefonnummer: 469-814-3524
- E-mail: shelby.mccoy@bswhealth.org
-
Ledende efterforsker:
- Aasim Afzal, MD
-
Temple, Texas, Forenede Stater, 76508
- Rekruttering
- Scott & White Memorial Hospital
-
Kontakt:
- Rohini Bagewadi
- Telefonnummer: 254-724-1083
- E-mail: rohini.bagewadi@bswhealth.org
-
Ledende efterforsker:
- Yevgeniy Khariton, MD
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84132
- Rekruttering
- University of Utah Hospital
-
Ledende efterforsker:
- Craig Selzman, MD
-
Kontakt:
- Ashley Elmer
- Telefonnummer: 801-585-6775
- E-mail: ashley.elmer@hsc.utah.edu
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- Rekruttering
- University of Virginia Medical Center
-
Kontakt:
- Tevin Jefferson
- Telefonnummer: 434-982-1058
- E-mail: MFU3QX@uvahealth.org
-
Ledende efterforsker:
- Mirnela Byku, MD
-
Richmond, Virginia, Forenede Stater, 23219
- Rekruttering
- Virginia Commonwealth University
-
Ledende efterforsker:
- Keyur Shah, MD
-
Kontakt:
- Saige Dagenhart
- Telefonnummer: 402-677-0237
- E-mail: Saige.Dagenhart@vcuhealth.org
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53215
- Rekruttering
- Aurora Medical Group
-
Ledende efterforsker:
- Nasir Sulemanjee, MD
-
Kontakt:
- Don Lobacz
- Telefonnummer: 414-649-3438
- E-mail: donald.lobacz@aah.org
-
-
-
-
Holland
-
Rotterdam, Holland, Holland, 3015 CE
- Rekruttering
- Erasmus MC - Thoraxcenter
-
Kontakt:
- Nico Van Den Berg
- Telefonnummer: +31-010-703-9307
- E-mail: n.berg@erasmusmc.nl
-
Ledende efterforsker:
- Rudolf De Boer, MD
-
-
Utrecht
-
Utrecht, Utrecht, Holland, 3584 CX
- Rekruttering
- UMC Utrecht
-
Ledende efterforsker:
- Linda Van Laake, MD
-
Kontakt:
- Manon Kuikhoven
- Telefonnummer: (088) 755-9432
- E-mail: m.j.kuikhoven@umcutrecht.nl
-
-
-
-
Piedmont
-
Turin, Piedmont, Italien, 10126
- Rekruttering
- A.O.U. Citta della Salute e della Scienza di Torino
-
Kontakt:
- Giuditta Cuccuru
- Telefonnummer: +39 011 6335351
- E-mail: gcuccuru@cittadellasalute.to.it
-
Ledende efterforsker:
- Antonino Loforte, MD
-
-
-
-
Riyadh Region
-
Riyadh, Riyadh Region, Saudi Arabien, 11525
- Rekruttering
- King Fahad Medical City
-
Ledende efterforsker:
- Mohammed Alreshidan, MD
-
Kontakt:
- Joud Hewaidi
- Telefonnummer: +966-530003751
- E-mail: jhewaidi@kfmc.med.sa
-
Riyadh, Riyadh Region, Saudi Arabien, 12713
- Rekruttering
- King Faisal Specialist Hospital
-
Kontakt:
- Luluah Altukhaifi
- Telefonnummer: +966 0556481098
- E-mail: laltukaifi@kfshrc.edu.sa
-
Ledende efterforsker:
- Jehad Abdulhamid Al Buraiki, MD
-
-
-
-
CBohmia
-
Prague, CBohmia, Tjekkiet, 14021
- Rekruttering
- IKEM Prague
-
Ledende efterforsker:
- Ivan Netuka, MD
-
Kontakt:
- Telefonnummer: +42 060 665 4220
- E-mail: martina.kucerova@ikem.cz
-
-
-
-
Saxon
-
Hanover, Saxon, Tyskland, 30625
- Rekruttering
- Medizinische Hochschule Hannover
-
Ledende efterforsker:
- Dominik Berliner, MD
-
Kontakt:
- Antje Juergens
- Telefonnummer: +49-0115-323-1113
- E-mail: juergens.antje@mh-hannover.de
-
-
Saxony
-
Leipzig, Saxony, Tyskland, 04289
- Rekruttering
- Herzzentrum Leipzig GmbH
-
Ledende efterforsker:
- Michael Borger, MD
-
Kontakt:
- Victoria Himstedt
- Telefonnummer: +49 341 865 25
- E-mail: victoria.himstedt@helios-health-institute.com
-
-
State of Berlin
-
Berlin, State of Berlin, Tyskland, 13353
- Rekruttering
- Deutsches Herzzentrum der Charité
-
Ledende efterforsker:
- Felix Schoenrath, MD
-
Kontakt:
- Annegret Schneider
- Telefonnummer: +49-304-593-2303
- E-mail: schneider@dhzb.de
-
-
-
-
State of Vienna
-
Vienna, State of Vienna, Østrig, 1090
- Rekruttering
- AKH -Wien
-
Kontakt:
- Julia Riebandt, MD, PhD
- Telefonnummer: +43 1 40400-69660
- E-mail: julia.riebandt@meduniwien.ac.at
-
Ledende efterforsker:
- Daniel Zimpfer, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Subject has provided written informed consent by signing the study Informed Consent Form (ICF) prior to any clinical investigation-related procedure
- LVEF ≤30% and Cardiac Index ≤ 2.5 L/min/m²
- Limited functional status as demonstrated by 6MWT ≤ 350 m due to HF related reasons OR peak VO2 ≤ 14 mL/kg/min (or <50% of predicted peak VO2 value)
- NYHA Class IIIB or NYHA Class IV
- Subject has ≥ 1 Heart Failure Hospitalization in the last 12 months
- Subject is already implanted with a CardioMEMS PA Sensor OR willing to undergo a CardioMEMS PA Sensor implant
- Subject is willing and able to be implanted with the HM3 LVAS if randomized to HM3 Group
Randomization Criteria:
- Subject has been implanted with a CardioMEMS PA Sensor for at least 90 days.
- Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
- mean PAP ≥ 30 mmHg.
- The subject will not be randomized if they have any other factor that represents inordinate risk for either continued GDMT or LVAD implant.
Single Arm Registry Criteria:
- Subject has received a CardioMEMS PA Sensor implant following enrollment in the trial.
- Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
- mean PAP <30 mmHg
Exclusion Criteria:
-
Subject is < 18 years of age at the time of informed consent.
-
Dependent on IV inotrope in the last 30 days.
-
Contra-indications to HM3 LVAS or CardioMEMS HF system.
-
Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or restrictive cardiomyopathy.
-
Technical obstacles to LVAD or CardioMEMS implantation which pose an inordinately high surgical risk, in the judgment of the implanter.
-
Existence of ongoing MCS.
-
Presence of mechanical aortic valve that will not be either converted to a bioprosthesis or oversewn at the time of LVAD implant.
-
History of any solid organ transplant.
-
Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management.
-
Presence of an active, uncontrolled infection.
-
Complex congenital heart disease.
-
Currently Pregnant or capable of becoming Pregnant and Unwilling to Use Contraception with LVAD.
-
History of pulmonary embolism within 30 days prior to enrollment or history of recurrent (>1 episode) pulmonary embolism and/or deep vein thrombosis.
-
Planned VAD or Bi-VAD support prior to enrollment.
-
Presence of any one of the following risk factors for or indications of severe end organ dysfunction or failure:
- An INR ≥ 2.0 not due to anticoagulation therapy
- An eGFR < 30 mL/min/1.73 m2 and nonresponsive to diuretic therapy or receiving chronic dialysis.
- Biopsy proven liver cirrhosis.
- Need for chronic renal replacement therapy.
- History of severe chronic obstructive pulmonary disease (COPD) defined by Forced Expiratory Volume FEV1 < 30% predicted.
- History of cerebrovascular disease with significant (> 80%) uncorrected internal carotid stenosis.
- Significant peripheral vascular disease (PVD) accompanied by ischemic rest pain or extremity ulceration.
-
Any condition other than HF that could limit survival to less than 24 months.
-
Participation in any other clinical investigation with an active treatment arm that is likely to confound study results or affect the study outcome.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Randomized Arm - HM3 Group
Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the HM3 group will receive the device within 14 days of randomization. |
The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
Andre navne:
The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.
Andre navne:
Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
Andre navne:
|
|
Eksperimentel: Randomized Arm - Control Group
Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the control group will continue their medical therapy per established heart failure guidelines. |
The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
Andre navne:
Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
Andre navne:
|
|
Eksperimentel: Single Arm Registry
Patients who do not meet the mean PAP threshold (mean PAP <30 mmHg) and are enrolled in the single arm will continue their medical therapy per established heart failure guidelines. |
The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
Andre navne:
Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Survival at 2 years free of disabling stroke, reoperation to replace the device, or worsening HF requiring listing for urgent heart transplantation or mechanical circulatory support, enrollment into hospice, or dependence on IV inotropes
Tidsramme: 2 years
|
The powered primary endpoint will be analyzed at 2 years following the Com-Nougue method and will be compared between the HM3 Group (HM3 LVAD) and the Control Group (GDMT) within the Intention-to-treat (ITT) population. |
2 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Rate of Safety Outcomes at 1-year
Tidsramme: 1 year
|
The powered secondary endpoint of Rate of Safety Outcomes at 1-year will be evaluated within the Intention-to-treat (ITT) population against a pre-specified performance goal. Components consist of the following:
|
1 year
|
|
Survival at 2 years
Tidsramme: 2 years
|
The powered secondary endpoint of survival at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. |
2 years
|
|
Quality of life score assessed with the Kansas City Cardiomyopathy Questionnaire
Tidsramme: 2 years
|
The secondary endpoint of Quality-of-life score at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Quality of life at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. The KCCQ scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life. Improvement of KCCQ by at least 10 points is considered clinically significant. |
2 years
|
|
Six-minute walk distance
Tidsramme: 2 years
|
The secondary endpoint of six-minute walk distance at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of six-minute walk distance at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
Hospitalizations for HF and/or Urgent HF Visit
Tidsramme: 2 years
|
The secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
Days alive and outside of the hospital
Tidsramme: 2 years
|
The secondary endpoint of days alive and outside of the hospital at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of days alive and outside of the hospital at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
All-cause hospitalizations
Tidsramme: 2 years
|
The secondary endpoint of all-cause hospitalizations at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all-cause hospitalizations at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
All adverse events (including all strokes) regardless of severity
Tidsramme: 2 years
|
The secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Finkelstein-Schoenfeld Win Ratio
Tidsramme: 5 years
|
The Finkelstein-Schoenfeld Win Ratio will be explored at 5 years as an additional analysis with the following hierarchy:
The Finkelstein-Schoenfeld Win Ratio will be analyzed between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the Finkelstein-Schoenfeld Win Ratio will be descriptively analyzed between the Single Arm and both the HM3 Group and Control Group of the Randomized Arm separately. |
5 years
|
|
Survival free of urgent LVAD or transplant
Tidsramme: 5 years
|
This additional descriptive analysis at 5-years will be performed to evaluate the proportion of patients who are alive and free of device replacement or transplant in the HM3 Group compared to the Single Arm Registry (de novo implant or transplant) |
5 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Kelly O'Connell, PhD, Abbott
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ABT- CIP-10521
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .